Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Metrics to compare | ACXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACXPPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −7.8x | −0.7x | |
PEG Ratio | −0.02 | 0.27 | 0.00 | |
Price/Book | 3.0x | 3.6x | 2.6x | |
Price / LTM Sales | - | 44.6x | 3.4x | |
Upside (Analyst Target) | 333.9% | 158.5% | 37.6% | |
Fair Value Upside | Unlock | −8.5% | 5.3% | Unlock |